Show simple item record

dc.contributor.authorWandrag, L
dc.contributor.authorBrett, SJ
dc.contributor.authorFrost, GS
dc.contributor.authorTo, M
dc.contributor.authorLoubo, EA
dc.contributor.authorJackson, NC
dc.contributor.authorUmpleby, AM
dc.contributor.authorBountziouka, V
dc.contributor.authorHickson, Mary
dc.date.accessioned2019-09-12T12:48:57Z
dc.date.available2019-09-12T12:48:57Z
dc.date.issued2019-09-11
dc.identifier.issn1745-6215
dc.identifier.issn1745-6215
dc.identifier.other561
dc.identifier.urihttp://hdl.handle.net/10026.1/14913
dc.description.abstract

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma patients with the aim of assessing the effect on skeletal muscle mass and function.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A randomised feasibility study was performed over six months in intensive care (ICU). Patients received 5 g L-EAA five times per day in addition to standard feed (L-EAA group) or standard feed only (control group) for up to 14 days. C-reactive protein, albumin, IL-6, IL-10, urinary 3-MH, nitrogen balance, protein turnover ([1-13C] leucine infusion), muscle depth change (ultrasound), functional change (Katz and Barthel indices) and muscle strength Medical Research Council (MRC) sum score to assess ICU Acquired Weakness were measured sequentially.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Eight patients (9.5% of screened patients) were recruited over six months. L-EAA doses were provided on 91/124 (73%) occasions. Inflammatory and urinary marker data were collected; serial muscle depth measurements were lacking due to short length of stay. Protein turnover studies were performed on five occasions. MRC sum score could not be performed as patients were not able to respond to the screening questions. The Katz and Barthel indices did not change. L-EAA delivery was achievable, but meaningful functional and muscle mass outcome measures require careful consideration in the design of a future randomised controlled trial.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>L-EAA was practical to provide, but we found significant barriers to recruitment and measurement of the chosen outcomes which would need to be addressed in the design of a future, large randomised controlled trial.</jats:p> </jats:sec> <jats:sec> <jats:title>Trial registration</jats:title> <jats:p>ISRCTN Registry, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1186/ISRCTN79066838">ISRCTN79066838</jats:ext-link>. Registered on 25 July 2012.</jats:p> </jats:sec>

dc.format.extent561-
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherBMC
dc.subjectMuscle wasting
dc.subjectEssential amino acids
dc.subjectLeucine
dc.subjectMuscle ultrasound
dc.subjectCritically ill
dc.subjectNitrogen balance
dc.subjectProtein turnover
dc.subjectMechanical ventilation
dc.subjectTrauma
dc.titleLeucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
dc.typejournal-article
dc.typeJournal Article
dc.typeRandomized Controlled Trial
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485257100003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue1
plymouth.volume20
plymouth.publication-statusPublished
plymouth.journalTrials
dc.identifier.doi10.1186/s13063-019-3639-2
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Health Professions
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Health and Community
plymouth.organisational-group/Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR)
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2019-08-08
dc.rights.embargodate2019-12-18
dc.identifier.eissn1745-6215
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1186/s13063-019-3639-2
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-09-11
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV